Business Context and Reporting Period
Company: Astronics Corporation
Filing Type: Form 8-K (Current Report)
Report Date: November 5, 2004
Event Date: November 2, 2004 (Notice of Delisting)
Context: The filing addresses a failure to satisfy Nasdaq continued listing standards regarding Audit Committee composition.
Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
- Audit Committee Vacancy: On October 31, 2004, John B. Drenning resigned from the Audit Committee because he did not meet independence standards (he was a partner in a law firm providing legal services to the Company).
- Non-Compliance: The Audit Committee temporarily operated with only two members, violating Nasdaq Marketplace Rule 4350(d)(2)(A), which requires at least three independent members.
- Delisting Notice: On November 2, 2004, Nasdaq notified the Company that its securities will be delisted at the opening of business on November 11, 2004, unless a hearing is requested.
Outlook, Risks, and Management Commentary
- Management Action: The Company intends to request a hearing from Nasdaq, which will stay the delisting pending a decision by the Nasdaq Listing Qualifications Panel.
- Remediation Plan: The Company plans to correct the noncompliance by appointing a new independent director who meets all Nasdaq and SEC independence standards.
- Risk: Immediate risk of delisting from The Nasdaq Stock Market if the hearing request is not filed or if the cure is not approved.
Key Facts for Investor Verification
- Verify the status of the Company's request for a hearing with Nasdaq to confirm if the delisting scheduled for November 11, 2004, has been stayed.
- Monitor announcements regarding the appointment of a new independent director to the Audit Committee.
- Confirm the Company's continued compliance with Nasdaq Marketplace Rule 4350(d)(4)(B) regarding the cure period.